The mammalian target of rapamycin (mTOR) inhibitor class of drugs represents the newest
addition to the armamentarium of therapies for hormonally driven breast cancer. It has …

Ligands for inhibitory immune receptors on T cells may be constitutively expressed on tumor
cells or host cells in tumor microenvironment as a consequence of adaptive immunity …

Clinical applications of novel anticancer agents in the past few decades brought marked
advances in cancer treatment, enabling remarkable efficacy and effectiveness; however …

Introduction: Targeted anticancer therapies act by interfering with defined molecular entities
and/or biologic pathways. Because of their more specific mechanism of action, adverse …

Breast cancer (BC) is diagnosed in nearly 1 in 3 women with cancer in the United States;
one third of these patients have regional lymph node metastases at the time of diagnosis …

Renal cell carcinoma (RCC) accounts for about 3% of all adult cancers and 85% to 90% of
all renal malignancies. 1 Approximately 46,000 new cases of RCC were diagnosed in 2008 …

The everolimus–exemestane combination is indicated in advanced breast cancer treatment
and usually well tolerated. The objective of the study was to determine the frequency of …

To date, oral everolimus is indicated for the treatment of patients with advanced renal cell
carcinoma, whose disease has progressed on or after treatment with vascular endothelial …

Background Mammalian target of rapamycin inhibitors may induce pneumonitis. We
analysed the association of pneumonitis with outcomes in everolimus treated metastatic …

OBJECTIVE. Renal cell carcinoma (RCC) has a propensity to metastasize to the chest, with
the lungs being the most common distant metastatic site. The histologic subtype of RCC has …